This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2017 Nov 21;318(19):1861-1862.

doi: 10.1001/jama.2017.15218.

FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug

Peter B Bach¹, Sergio A Giralt¹, Leonard B Saltz¹

Affiliations

PMID: 28975266
DOI: 10.1001/jama.2017.15218

FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug

Peter B Bach et al. JAMA. 2017.

. 2017 Nov 21;318(19):1861-1862.

doi: 10.1001/jama.2017.15218.

Authors

Peter B Bach¹, Sergio A Giralt¹, Leonard B Saltz¹

Affiliation

¹ Memorial Sloan Kettering Cancer Center, New York, New York.

PMID: 28975266
DOI: 10.1001/jama.2017.15218

No abstract available

PubMed Disclaimer

Similar articles

Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
[No authors listed] [No authors listed] J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx173. J Natl Cancer Inst. 2017. PMID: 29117395 No abstract available.
Expensive cancer therapies: unintended effects.
Delude CM. Delude CM. J Natl Cancer Inst. 2015 Jan 6;107(1):497. doi: 10.1093/jnci/dju497. Print 2015 Jan. J Natl Cancer Inst. 2015. PMID: 25564602 No abstract available.
Promising drug is victim of bad business.
Dove A. Dove A. Nat Med. 2002 Mar;8(3):199. doi: 10.1038/nm0302-199a. Nat Med. 2002. PMID: 11875472 No abstract available.
Cancer drug approval in the United States, Europe, and Japan.
Milsted RA. Milsted RA. Adv Cancer Res. 2007;96:371-91. doi: 10.1016/S0065-230X(06)96012-6. Adv Cancer Res. 2007. PMID: 17161686 Review. No abstract available.
Assessing tumor-related signs and symptoms to support cancer drug approval.
Williams G, Pazdur R, Temple R. Williams G, et al. J Biopharm Stat. 2004 Feb;14(1):5-21. doi: 10.1081/BIP-120028503. J Biopharm Stat. 2004. PMID: 15027497 Review.

See all similar articles

Cited by

A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer.
Muscarella P, Bekaii-Saab T, McIntyre K, Rosemurgy A, Ross SB, Richards DA, Fisher WE, Flynn PJ, Mattson A, Coeshott C, Roder H, Roder J, Harrell FE, Cohn A, Rodell TC, Apelian D. Muscarella P, et al. J Pancreat Cancer. 2021 Mar 23;7(1):8-19. doi: 10.1089/pancan.2020.0021. eCollection 2021. J Pancreat Cancer. 2021. PMID: 33786412 Free PMC article.
Forefronts and hotspots evolution of the nanomaterial application in anti-tumor immunotherapy: a scientometric analysis.
Cao W, Jin M, Zhou W, Yang K, Cheng Y, Chen J, Cao G, Xiong M, Chen B. Cao W, et al. J Nanobiotechnology. 2024 Jan 13;22(1):30. doi: 10.1186/s12951-023-02278-3. J Nanobiotechnology. 2024. PMID: 38218872 Free PMC article.
Pemphigus: Current and Future Therapeutic Strategies.
Didona D, Maglie R, Eming R, Hertl M. Didona D, et al. Front Immunol. 2019 Jun 25;10:1418. doi: 10.3389/fimmu.2019.01418. eCollection 2019. Front Immunol. 2019. PMID: 31293582 Free PMC article. Review.
Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs.
Guo S, Xi X. Guo S, et al. Biomark Res. 2025 Mar 11;13(1):41. doi: 10.1186/s40364-025-00755-5. Biomark Res. 2025. PMID: 40069884 Free PMC article. Review.
Next-generation CAR T cells to overcome current drawbacks.
Lundh S, Maji S, Melenhorst JJ. Lundh S, et al. Int J Hematol. 2021 Nov;114(5):532-543. doi: 10.1007/s12185-020-02923-9. Epub 2020 Jun 27. Int J Hematol. 2021. PMID: 32594314 Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations